Research led by the Hubrecht Institute and the University Medical Center Utrecht has uncovered a key molecular mechanism that helps control heart regeneration in zebrafish. A protein known as leucine-rich repeat-containing 10 (LRRC10) acts as a switch to stop uncontrolled proliferation of cardiomyocyte cells when regeneration is complete. As reported in the May 18, 2023, issue of Science, lead author Jeroen Bakkers and colleagues found that the LRRC10 pathway was conserved in mouse and human cells. Read More
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by a chromosomal translocation that results in the generation of the BCR-ABL1 oncogene, which encodes the chimeric BCR-ABL1 protein with tyrosine kinase activity. Allosteric tyrosine kinase inhibitors (TKIs) represent an improvement of 2-fold in efficacy over standard inhibitors and are better tolerated. Read More
Exo Therapeutics Inc. has announced its lead program directed against TANK-binding kinase 1 (TBK1) for the treatment of autoimmune diseases. The company is now approaching identification of a development candidate for its lead program, an exosite-targeted compound that selectively reprograms the activity of TBK1 in the STING pathway that drives pathogenic signaling in diseases such as systemic lupus erythematosus, Aicardi-Goutières syndrome and others. Read More
Researchers from the University of Maryland presented preclinical data for YA-6060, a novel small molecule showing dual activities of Wnt inhibition and AMPK activation via the mechanism of AXIN stabilization. Since both Wnt/β-catenin and AMPK signaling pathways have been previously shown to play a key role in liver fibrosis, this study aimed to assess the potential of YA-6060 as an antifibrosis agent. Read More
Cancer Research Technology Ltd. and Merck KGaA have jointly patented tricyclic heterocycles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors. Read More
Antengene Corp. Ltd.'s Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 has been granted two orphan drug designations consecutively by the FDA for the treatment of gastric cancer and pancreatic cancer. Read More
A recent Twentyeight-Seven Inc. patent describes dual specificity protein kinase CLK3 inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Kyungpook National University presented data from a study that aimed to investigate the endogenous mechanisms involved in granule cell dispersion (GCD) and its role in epileptic seizures in temporal lobe epilepsy (TLE). Read More
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified piperazinylsulfonylaryl compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors. Read More
Research at Reunion Neuroscience Inc. has led to the discovery of benzyltryptamine compounds acting as 5-HT2A receptor agonists. These compounds are reported to be useful for the treatment of depression, alcoholism, cocaine addiction, inflammation, cluster headache neurological and post-traumatic stress disorder. Read More
Bioray Pharmaceutical Co. Ltd.’s IND application for BRY-812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration (NMPA). Read More
A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors. Read More
Pharmabcine Inc. has received IND approval from the Korean Ministry of Food and Drug Safety (MFDS) to initiate a phase I trial of PMC-403 in Korea in subjects with neovascular (wet) age-related macular degeneration (AMD). Read More
At the recent ASPET meeting, University of Minnesota and University of Montana researchers presented data from studies to determine the ability of the Toll-like receptor 7 (TLR7) and TLR8 agonist INI-4001 to enhance the efficacy of the heroin vaccine M-sKLH for the treatment of opioid use disorder. Read More
